A statement released earlier today by RBC Capital Markets about Aptose Biosciences (TSE:APS) bumps the target price to $24.00
- Updated: October 14, 2016
Boasting a price of $3.00, Aptose Biosciences (TSE:APS) traded -8.44% lower on the day. With the last stock price close down -8.86% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Aptose Biosciences has recorded a 50-day average of $2.90 and a two hundred day average of $3.21. Volume of trade was up over the average, with 62,650 shares of APS changing hands over the typical 18,514
RBC Capital Markets bumped up the target of Aptose Biosciences (TSE:APS) to $24.00 stating a potential upside of 7%.
With a total market value of $0, Aptose Biosciences has with a one year low of $2.51 and a one year high of $8.33 .
A total of 3 firms have released a research note on APS. 1 brokerage rating the company a strong buy, two analysts rating the stock a buy, 0 brokerages rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 analysts rating the company a sell with a one year target of $10.96.
Brief Synopsis About Aptose Biosciences (TSE:APS)
Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.